Fig. 1. Drug survival curve for patients treated with a fully human anti‐TNF moAb (D2E7; n=61) or MTX (n=137). Percentage of patients still on therapy.

Slides:

Advertisements

Similar presentations

Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:

Advertisements

Treatment Management of Rheumatoid Arthritis. Findings and In Depth Analysis.

Marc Bonin Department of Rheumatology and Clinical Immunology Charité University Hospital Charitéplatz 1 D Berlin Germany Tel: +49(0)

Tumor necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis The Annals of the.

A NEW LOOK AT RA Interactive Hot Topics Series

Fig. 1 Flow chart of the COBRA-light trial and its extension study

Volume 18, Issue 2, Pages (March 2015)

A NEW LOOK AT RA Interactive Hot Topics Series

Ann Intern Med. 1999;130(6): doi: / Figure Legend:

pSS: primary SS; Scl: scleroderma.

Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).

Fig. 1. Percentage of patients with AS, with RA and of normal controls responding to the in vitro stimulation with the G1 domain of the proteoglycan aggrecan.

Fig. 1. Sonographic-guided injection of steroid in the metacarpophalangeal joint of a patient with rheumatoid arthritis (8–16 MHz linear transducer, Diasus,

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

Comparative analysis of TNF-inhibitor survival in spondyloarthritis: data from the Hellenic Registry of Biologic Therapies P Sidiropoulos Rheumatology,

Clinical Developments in Inflammatory Arthritis 2017

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

L. S. Tzouvelekis, A. Markogiannakis, E. Piperaki, M. Souli, G. L

Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications T.-L. Liao, Y.-M.

Radiographic progression among three therapy groups (triple therapy group, anti-TNF treatment group and MTX responders) stratified by MBDA categories at.

BeSt Study: Patient Characteristics Total Population Female 67% Male % Age (years) Duration of symptoms (weeks) 23 Time diagnosis.

Percentage of patients achieving DAS28 (CRP) < 3

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

ADAb: anti-drug antibody.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

N.M.A. Blijlevens, J.P. Donnelly, B.E. de Pauw

Changes in clinical disease activity over 24 months on a continuous scale in SWEFOT trial participants randomised to triple therapy or anti-TNF with available.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

Fig. 1. Clinical course, treatment and titres of anti-ssDNA antibodies

HAQ-DI change from baseline and proportion of patients achieving MCID after 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination.

ACR response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or in combination with cDMARDs or MTX. The proportions of patients.

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Fig. 1 Flow chart of included patients for analyses

Rats were treated for 21 days ...

Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis

Percentage of patients reporting improvements ≥MCID and NNTs to achieve an MCID in (A) PtGA, (B) pain, (C) HAQ-DI, (D) FACIT-F and (E) SF-36 domains and.

Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA seronegative status. Cumulative probability of time.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Response rates for patients achieving 50% (A), 70% (B), and 90% (C) improvement in ACR criteria, and normal physical function (D) over the course of 10.

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Matrix risk model showing the probability of SRP in patients with moderate disease activity after 3 years of MTX treatment. Matrix risk model showing the.

Multivariate analysis for SRP after 3 years in patients with moderate disease activity despite MTX treatment. Multivariate analysis for SRP after 3 years.

Clinical response in patients with early and established RA at month 24. *p

Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.

Percentage of patients with RA achieving DAS28(CRP)<2

Relative treatment effects concerning efficacy endpoints in patients with inadequate response to methotrexate for triple therapy versus TNFi–methotrexate.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI

Patient disposition after 2 years of treatment.

Study design. *Randomisation stratified by corticosteroid use at baseline. Study design. *Randomisation stratified by corticosteroid use at baseline. DAS28-CRP,

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Mean profiles over 1 year from the observed Disease Activity Score 28 (DAS28) data for the methotrexate (MTX)-exposed patients after stratifying by predicted.

Treatment Advances for RA

DAPSA LSM change from baseline (A), patients achieving DAPSA ≤28 (MDA) (B), DAPSA ≤14 (LDA) (C) or DAPSA ≤4 (REM) (D) after 24 weeks in patients treated.

Patient-level radiographic progression of structural joint damage at year 1 and year 2 by original randomisation. Patient-level radiographic progression.

Patient disposition over the 52-week study period

Multivariable model of adjusted

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

ACR20, ACR20 and ACR70 response rates (proportions of patients meeting ACR 20, 50% or 70% improvement criteria) in patients with rheumatoid arthritis randomised.

Percentage of patients achieving remission by conversion to ACPA seronegative status. Percentage of patients achieving remission by conversion to ACPA.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

ACR20 (A), ACR50 (B) and MDA (C) response rates at 24 weeks in patients treated with PBO, IXEQ4W or IXEQ2W alone or when added to background cDMARDs or.

(A) Percentage of patients achieving remission or response at week 12 or 24 after initiating ova therapy. (A) Percentage of patients achieving remission.

Presentation transcript:

Fig. 1. Drug survival curve for patients treated with a fully human anti‐TNF moAb (D2E7; n=61) or MTX (n=137). Percentage of patients still on therapy on the y‐axis. Time in weeks on the x‐axis. From: Drug survival, efficacy and toxicity of monotherapy with a fully human anti‐tumour necrosis factor‐α antibody compared with methotrexate in long‐standing rheumatoid arthritis Rheumatology (Oxford). 2002;41(4):430-439. doi:10.1093/rheumatology/41.4.430 Rheumatology (Oxford) | © British Society for Rheumatology

Fig. 2. Clinical response in patients treated with human anti‐TNF moAb (D2E7; n=61) or MTX (n=137) monotherapy. Percentages of good and moderate responders (open and solid symbols, respectively) according to the EULAR criteria. Time in weeks on the x‐axis. MTX and D2E7 are represented as triangles and boxes, respectively. ▪, □, anti‐TNF therapy; ▵, MTX. From: Drug survival, efficacy and toxicity of monotherapy with a fully human anti‐tumour necrosis factor‐α antibody compared with methotrexate in long‐standing rheumatoid arthritis Rheumatology (Oxford). 2002;41(4):430-439. doi:10.1093/rheumatology/41.4.430 Rheumatology (Oxford) | © British Society for Rheumatology

Fig. 3. Course of the DAS during 48 weeks of therapy with anti‐TNF (n=61) or MTX (n=137) monotherapy. DAS on the y‐axis. Time in weeks on the x‐axis. From: Drug survival, efficacy and toxicity of monotherapy with a fully human anti‐tumour necrosis factor‐α antibody compared with methotrexate in long‐standing rheumatoid arthritis Rheumatology (Oxford). 2002;41(4):430-439. doi:10.1093/rheumatology/41.4.430 Rheumatology (Oxford) | © British Society for Rheumatology